1 reports of this reaction
16.7% of all THUJA OCCIDENTALIS LEAFY TWIG reports
#4 most reported adverse reaction
HAEMATOCHEZIA is the #4 most commonly reported adverse reaction for THUJA OCCIDENTALIS LEAFY TWIG, manufactured by BM Private Limited. There are 1 FDA adverse event reports linking THUJA OCCIDENTALIS LEAFY TWIG to HAEMATOCHEZIA. This represents approximately 16.7% of all 6 adverse event reports for this drug.
Patients taking THUJA OCCIDENTALIS LEAFY TWIG who experience haematochezia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATOCHEZIA is a frequently reported adverse event for THUJA OCCIDENTALIS LEAFY TWIG, accounting for a significant proportion of all reports.
In addition to haematochezia, the following adverse reactions have been reported for THUJA OCCIDENTALIS LEAFY TWIG:
The following drugs have also been linked to haematochezia in FDA adverse event reports:
HAEMATOCHEZIA has been reported as an adverse event in 1 FDA reports for THUJA OCCIDENTALIS LEAFY TWIG. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATOCHEZIA accounts for approximately 16.7% of all adverse event reports for THUJA OCCIDENTALIS LEAFY TWIG, making it a notable side effect.
If you experience haematochezia while taking THUJA OCCIDENTALIS LEAFY TWIG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.